Stock COMBI COMBIGENE AB
Add to a list
To use this feature you must be a member
Log inSign up

Company CombiGene AB

Equities

COMBI

SE0016101935

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 09:56:06 2024-04-25 am EDT 		5-day change 1st Jan Change
3.76 SEK -1.05% Intraday chart for CombiGene AB -2.34% +39.78%
Mar. 13 CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries CI
Feb. 21 Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI). CI

Business Summary

Combigene AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.

Number of employees: 11

Sales per Business

SEK in Million2021Weight2022Weight Delta
Novel Gene Therapies
100.0 %
84 100.0 % 27 100.0 % -68.23%

Sales per region

SEK in Million2021Weight2022Weight Delta
Sweden
100.0 %
84 100.0 % 27 100.0 % -68.23%

Managers

Managers TitleAgeSince
Peter Ekolind CEO
 Chief Executive Officer 60 22-09-26
Louise Aspenberg DFI
 Director of Finance/CFO 48 20-10-11
Daniela Morath ADM
 Chief Administrative Officer 44 17-12-31
Karin Agerman CTO
 Chief Tech/Sci/R&D Officer 51 17-12-31

Members of the board

Members of the board TitleAgeSince
Gunilla Lundmark BRD
 Director/Board Member 61 20-12-31
Jonas Göran Ekblom BRD
 Director/Board Member 59 19-12-31
Ulf Peter Nilsson BRD
 Director/Board Member 54 14-09-30
Per Lundin BRD
 Director/Board Member 41 -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 19,801,197 13,769,476 ( 69.54 %) 0 69.54 %

Company contact information

CombiGene AB

Agavägen 52A

181 55, Lidingoe

+46 7 04 66 31 63

http://www.combigene.com
address CombiGene AB(COMBI)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sector Bio Therapeutic Drugs

1st Jan change Capi.
COMBIGENE AB Stock CombiGene AB
+39.78% 6.91M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.26% 104B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 97.42B
ARGENX SE Stock argenx SE
+0.79% 22.2B
BIONTECH SE Stock BioNTech SE
-17.84% 21.23B
GENMAB A/S Stock Genmab A/S
-11.11% 18.33B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.35B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.63% 15.06B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.55% 13.98B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.11% 11.66B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. COMBI Stock
  4. Company CombiGene AB